[1]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149-150.[doi:10.3969/j.issn.1006-1959.2020.04.048]
 FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2020,33(05):149-150.[doi:10.3969/j.issn.1006-1959.2020.04.048]
点击复制

多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年05期
页码:
149-150
栏目:
药物与临床
出版日期:
2020-03-01

文章信息/Info

Title:
Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer
文章编号:
1006-1959(2020)04-0149-02
作者:
付大鹏
(解放军联勤保障部队九六七医院肿瘤科,辽宁 大连 116000)
Author(s):
FU Da-peng
(Department of Oncology,967 Hospital of PLA Joint Service,Dalian 116000,Liaoning,China)
关键词:
乳腺癌多西他赛表柔比星新辅助化疗
Keywords:
Breast cancerDocetaxelEpirubicinNeoadjuvant chemotherapy
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.04.048
文献标志码:
A
摘要:
目的 研究多西他赛联合表柔比星新在乳腺癌辅助化疗治疗中的应用效果。方法 选取2017年1月~2018年7月在我院诊治的110例乳腺癌患者为研究对象,随机分为对照组和观察组,各55例。对照组采用紫杉醇联合表柔比星化疗,观察组采用多西他赛联合表柔比星化疗,比较两组临床缓解率、卡氏评分、体力状况评分、毒副反应(胃肠反应、白细胞下降、外周静脉炎)发生率、复发率以及生存时间。结果 观察组临床治疗缓解率为81.81%,与对照组的78.18%比较,差异无统计学意义(P>0.05);治疗后两组卡氏评分高于治疗前,体力状况评分低于治疗前,且观察组优于对照组(P<0.05);观察组毒副反应发生率低于对照组(P<0.05);随访1年,观察组复发率低于对照组,生存时间长于对照组(P<0.05)。结论 多西他赛联合表柔比星新辅助化疗与紫杉醇疗效类似,但在延长生存时间、改善身体状况、降低复发率方面有一定优势,且毒副反应少,值得应用。
Abstract:
Objective To study the effect of docetaxel combined with epirubicin in neoadjuvant chemotherapy for breast cancer.Methods A total of 110 patients with breast cancer diagnosed and treated in our hospital from January 2017 to July 2018 were selected as the research subjects, and they were randomly divided into a control group and an observation group, with 55 cases in each group. The control group was treated with paclitaxel combined with epirubicin chemotherapy, and the observation group was treated with docetaxel combined with epirubicin chemotherapy. The two groups were compared for clinical remission rate, Karst score, physical condition, toxic and side effects (gastrointestinal reaction, leukopenia, Peripheral phlebitis) incidence, recurrence rate and survival time. Results The clinical treatment response rate in the observation group was 81.81%, compared with 78.18% in the control group,the difference was not statistically significant (P>0.05). After treatment, the Karst score was higher than before, and the physical condition score was lower than before. And the observation group was better than the control group(P<0.05); the incidence of toxic and side effects in the observation group was lower than the control group(P<0.05); During a follow-up of 1 year, the recurrence rate in the observation group was lower than that in the control group, and the survival time was longer than that in the control group(P<0.05).Conclusion Docetaxel combined with epirubicin neoadjuvant chemotherapy has similar efficacy to paclitaxel, but it has certain advantages in prolonging survival time, improving physical condition, and reducing recurrence rate, and has fewer toxic and side effects, and is worth applying.

参考文献/References:

[1]刘丽娟,赖雁威.TEC方案在晚期乳腺癌新辅助化疗(NCT)中的疗效分析[J].中国医院药学杂志,2014,34(16):1391-1395.[2]朱晴晴.多西他赛、表柔比星和环磷酰胺在乳腺癌新辅助化疗中的疗效观察[J].中国社区医师,2016,32(14):62-63.[3]王雪梅.乳腺癌新辅助化疗中多西他赛表柔比星联合环磷酰胺的应用价值[J].心理医生,2017,23(8):8-9.[4]Yaghjyan L,Colditz GA,Rosner B,et al.Mammographic breast density and breast cancer risk: interactions of percent density,absolute dense,and non-dense areas with breast cancer risk factors[J].Breast Cancer Research and Treatment,2015,150(1):181-189.[5]刘婷婷,蔡倩,徐航,等.表柔比星联用紫杉醇或多西他赛在Ⅲ期乳腺癌新辅助化疗中的疗效研究[J].临床合理用药杂志,2016,9(14):50-51.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
 DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
 ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Medical Information,2022,35(05):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
 YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(05):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘雪静,路 红,徐熠琳,等.乳腺影像与容积导航技术初步应用的临床分析[J].医学信息,2022,35(11):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
 LIU Xue-jing,LU Hong,XU Yi-lin,et al.Clinical Analysis of the Preliminary Application of Breast Imaging and Volume Navigation Technology[J].Medical Information,2022,35(05):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
[6]刘在波,修文娟.背阔肌皮瓣联合假体在乳腺癌改良根治术后乳房重建中的应用[J].医学信息,2019,32(02):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
 LIU Zai-bo,XIU Wen-juan.Application of Latissimus Dorsi Flap Combined with Prosthesis in Breast Reconstruction after Modified Radical Mastectomy for Breast Cancer[J].Medical Information,2019,32(05):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
[7]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
 ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(05):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[8]孟庆国,王佳雪,王斯佳.马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J].医学信息,2019,32(02):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
 MENG Qing-guo,WANG Jia-xue,WANG Si-jia.Effect of Pyrrolidine Maleate on Cardiac Function in Patients after Breast Cancer Operation[J].Medical Information,2019,32(05):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
[9]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
 LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,31(05):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[10]满枋霖,葛俊宏,林晓月,等.p21活化激酶在乳腺癌中的作用研究[J].医学信息,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
 MAN Fang-lin,GE Jun-hong,LIN Xiao-yue,et al.The Role of p21 Activated Kinase in Breast Cancer[J].Medical Information,2019,32(05):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
[11]王启平,兰安宁,吴晓峰.低剂量地塞米松对乳腺癌化疗不良反应的影响[J].医学信息,2020,33(14):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
 WANG Qi-ping,LAN An-ning,WU Xiao-feng.Effect of Low-dose Dexamethasone on Adverse Reactions of Chemotherapy in Breast Cancer[J].Medical Information,2020,33(05):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]

更新日期/Last Update: 2020-03-01